US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Protagenic Therapeutics, Inc. - Common Stock
(NQ:
PTIX
)
0.7400
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagenic Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
August 20, 2026
From
Protagenic Therapeutics, Inc.
Via
ACCESS Newswire
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
June 30, 2026
From
Protagenic Therapeutics, Inc.
Via
ACCESS Newswire
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
May 19, 2026
Via
ACCESS Newswire
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
April 23, 2026
Via
ACCESS Newswire
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
April 17, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
April 01, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
March 27, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
March 17, 2026
Via
ACCESS Newswire
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
March 10, 2026
Via
ACCESS Newswire
Results from Phase 1 Multiple-Dose Study of PT00114
December 09, 2025
Via
ACCESS Newswire
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
November 13, 2025
Via
ACCESS Newswire
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
August 22, 2025
Via
ACCESS Newswire
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
March 25, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
February 13, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
September 26, 2023
Via
ACCESSWIRE
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
August 21, 2025
Via
ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
May 27, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
March 22, 2023
Via
ACCESSWIRE
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
May 21, 2025
Via
ACCESS Newswire
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
May 19, 2025
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 19, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
May 19, 2025
Via
ACCESS Newswire
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
April 29, 2025
Via
ACCESS Newswire
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
November 05, 2024
Via
ACCESSWIRE
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
May 22, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
May 01, 2024
Via
ACCESSWIRE
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
March 21, 2024
Via
ACCESSWIRE
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
April 26, 2022
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic...
From
Protagenic Therapeutics, Inc.
Via
AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
July 08, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are...
From
Access to Giving
Via
AccessWire
< Previous
1
2
Next >
